pad4

GSK484 hydrochloride (GTPL8577) 是一种可逆的肽酰基精氨酸脱亚氨酶 4 (PAD4) 抑制剂。它高亲和力与 PAD4 结合，在存在 2 mM 钙和不存在钙的情况下，IC50分别为 250 和 50 nM。GSK484 可以在体内和体外促进结直肠癌（CRC）的放射敏感性并抑制 NET 的形成。

Bongkrekic acid (Bongkrekic Acid (ammonium salt)) 是一种由伯克霍尔德菌（Burkholderia gladioli）分泌的线粒体毒素，抑制腺嘌呤核苷酸转位酶 （ANT）。Bongkrekic acid Bongkrekic acid 通过 p38、ERK、PAD4 和 P2X1 介导的信号传导诱导中性粒细胞胞外陷阱。

Streptonigrin is a natural product produced by Streptomyces flocculus, has both anti-tumor and anti-bacterial activity. Streptonigrin acts as a pan-PAD inhibitor (IC50s: 48.3±34.2 µM, 26.1±0.3 µM, 0.43±0.03 µM, and 2.5±0.4 µM for PAD1, PAD2, PAD3, and PAD

Cl-amidine is an orally active inhibitor of peptidyl arginine deminase (PAD) (IC50s: 0.8 μM, 6.2 μM, and 5.9 μM for PAD1, PAD3, and PAD4). Cl-amidine induces apoptosis in cancer cells.

Cl-amidine hydrochloride 是一种口服有效的PAD抑制剂，可阻断组蛋白3去亚胺化和中性粒细胞胞外陷阱的形成，并提高败血症小鼠的存活率。它可诱导癌细胞凋亡，还可诱导 miR-16 引起细胞周期阻滞。

GSK199 是可逆的 PAD4选择性抑制剂，当缺少钙离子时，其 IC50值为 200 nM。

BMS-P5 是一种特异性具有口服活性的肽精氨酸二亚胺酶 4抑制剂。它可阻断多发性骨髓瘤诱导的 NET 形成，并延缓肿瘤进程。

PAD4-IN-2（化合物5i）是一种具有IC50为1.94 μM的PAD4抑制剂。该化合物能够通过特异性抑制中性粒细胞内PAD4-H3cit-NETs途径，从而有效抑制小鼠体内肿瘤生长。

PAD4-IN-3（compound 4B）是PAD4抑制剂，表现出体内外的抗肿瘤活性。该化合物通过共价连接RGD序列肽修饰的壳聚糖（K-CRGDV），形成增强的氧化应激反应性纳米剂。K-CRGDV-PAD4-IN-3能够主动靶向肿瘤，抑制PAD4活性，阻断中性粒细胞胞外陷阱（NET）的形成，并通过改善肿瘤免疫微环境来响应肿瘤微环境。

Cl-amidine TFA is an orally active inhibitor of peptidyl arginine deminase (PAD) with IC50 values of 0.8 μM, 6.2 μM, and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine induces apoptosis in cancer cells.

BMS-P5 free base 是一种特异性，可口服的肽精氨酸二亚胺酶抑制剂，可阻断多发性骨髓瘤诱导的 NET 形成，并延缓肿瘤进程。

GSK121 Trifluoroacetate 是PAD4的选择性抑制剂。

F-amidine is a bioavailable irreversible PAD4 inactivator.

GSK106 is a negative control used in binding and functional assays for PAD4 inhibitors.

YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor, with an IC50 of 1-5 μM for PAD4. Compared with Cl-amidine, YW3-56 shows >60-fold increase in cell growth inhibition efficacy (IC50 about 2.5 μM) but only 5-fold increase in PAD4 inhibition (IC sub>50 about 1-5 μM). At 2-4 μM concentrations, YW3-56 displays mainly cytostatic effects by slowing cell division, whereas at higher concentrations, it exerts cytotoxic effects by altering cell morphology and killing cells[1]. [1]. Wang Y, et al. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and t he mammalian target of rapamycin complex 1 activity. J Biol Chem. 2012 Jul 27;287(31):25941-53.

YW3-56 is an inhibitor of protein arginine deiminase 2 (PAD2) and PAD4 (IC50s = 0.5-1 and 1-5 μM, respectively).1It inhibits the growth of U2OS osteosarcoma cells (IC50= ~2.5 μM) in a p53-dependent mannerviainduction of SESN2 and subsequent inhibition of mTORC1. YW3-56 (10 mg kg) reduces tumor growth in an S-180 murine sarcoma tumor model. It also inhibits tumor growth in the 1883 MDA-MB-231 breast cancer bone metastasis mouse xenograft model.2 1.Wang, Y., Li, P., Wang, S., et al.Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activityThe Journal of Biological Chemisty287(31)25941-25952(2012) 2.Wang, S., Chen, X.A., Hu, J., et al.ATF4 gene network mediates cellular response to the anticancer PAD inhibitor YW3-56 in triple-negative breast cancer cellsMol. Cancer Ther.14(4)877-888(2015)

PAD2-IN-1, a benzimidazole-based derivative, is an efficacious and specific inhibitor of protein arginine deiminase 2 (PAD2). Demonstrating remarkable selectivity, PAD2-IN-1 exhibits a 95-fold higher affinity for PAD2 in comparison to PAD4 and a 79-fold higher affinity than PAD3.

PAD-IN-2 是 pad4 的有效抑制剂，IC50 值 <1 μM，能够用于研究自身免疫性疾病和癌症，如类风湿性关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、囊性纤维化、溃疡性结肠炎、哮喘、多发性硬化和牛皮癣。

PAD2-IN-1 hydrochloride 是有效的、选择性的蛋白精氨酸脱亚氨酶 2 (PAD2) 抑制剂，且对 PAD2 的选择性优于 PAD4 (95 倍) 和 PAD3 (79 倍)，是一种基于苯并咪唑的衍生物。

JBI-589为一种非共价、选择性PAD4抑制剂，可降低CXCR2表达，阻断中性粒细胞趋化性；此外，JBI-589能减小原发肿瘤体积及其转移，并增强检查点抑制剂的抗肿瘤效果。

F-amidine is a selective inhibitor of protein arginine deiminases (PADs), specifically targeting PAD1 and PAD4 with in vitro IC50 values of 29.5, 350, and 21.6 µM for PAD1, PAD3, and PAD4, respectively. It irreversibly inactivates all four PAD subtypes by covalently modifying an active site cysteine crucial for enzymatic activity, with kinact/KI values of 2,800, 380, 170, and 3,000 M^-1min^-1. Additionally, F-amidine demonstrates cytotoxicity against HL-60, MCF-7, and HT-29 cancer cell lines, with IC50s of 0.5, 0.5, and 1 μM, respectively.

GSK484 是一种有效且可逆的肽酰基精氨酸脱亚氨酶 4 (PAD4) 抑制剂。GSK484 与 PAD4 结合具有高亲和力。